- Home
- YQ vs RDHL Comparison
YQ vs RDHL Comparison
Compare YQ & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YQ
- RDHL
- Stock Information
- Founded
- YQ 2012
- RDHL 2009
- Country
- YQ China
- RDHL Israel
- Employees
- YQ N/A
- RDHL N/A
- Industry
- YQ Other Consumer Services
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- YQ Real Estate
- RDHL Health Care
- Exchange
- YQ Nasdaq
- RDHL Nasdaq
- Market Cap
- YQ 19.4M
- RDHL 4.3M
- IPO Year
- YQ 2020
- RDHL N/A
- Fundamental
- Price
- YQ $2.28
- RDHL $2.18
- Analyst Decision
- YQ
- RDHL
- Analyst Count
- YQ 0
- RDHL 0
- Target Price
- YQ N/A
- RDHL N/A
- AVG Volume (30 Days)
- YQ 58.8K
- RDHL 17.8K
- Earning Date
- YQ 09-03-2025
- RDHL 08-28-2025
- Dividend Yield
- YQ N/A
- RDHL N/A
- EPS Growth
- YQ N/A
- RDHL N/A
- EPS
- YQ N/A
- RDHL N/A
- Revenue
- YQ $25,546,613.00
- RDHL $8,042,999.00
- Revenue This Year
- YQ N/A
- RDHL $381.91
- Revenue Next Year
- YQ N/A
- RDHL N/A
- P/E Ratio
- YQ N/A
- RDHL N/A
- Revenue Growth
- YQ N/A
- RDHL 23.17
- 52 Week Low
- YQ $1.26
- RDHL $1.71
- 52 Week High
- YQ $3.19
- RDHL $20.28
- Technical
- Relative Strength Index (RSI)
- YQ 57.45
- RDHL 65.22
- Support Level
- YQ $2.15
- RDHL $2.00
- Resistance Level
- YQ $2.28
- RDHL $2.08
- Average True Range (ATR)
- YQ 0.15
- RDHL 0.09
- MACD
- YQ 0.00
- RDHL 0.03
- Stochastic Oscillator
- YQ 54.29
- RDHL 97.73
About YQ 17 Education & Technology Group Inc.
17 Education & Technology Group Inc is an education technology company in China. It offers smart, in-school, teaching and learning SaaS offerings assist students, teachers, schoolmasters and educational authorities across China. It also offer other educational products and services that complement students' in-school learning. Geographically group operates in China.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.